As Covid-19 R&D goes in­to over­drive, nuts-and-bolts bio­phar­ma re­search is hit­ting the skids. How bad is it?

Typ­i­cal­ly, word that the mi­cro­cap Swiss biotech Ad­dex had de­layed a key clin­i­cal tri­al wouldn’t gar­ner much at­ten­tion.

To­day, though, it’s an­oth­er ear­ly sign that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.